|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/422 | (2006.01) |
| A61P 9/12 | (2006.01) | ||
| A61K 9/20 | (2006.01) | ||
| A61P 13/12 | (2006.01) |
| (11) | Number of the document | 3222277 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17157697.8 |
| Date of filing the European patent application | 2010-03-29 | |
| (97) | Date of publication of the European application | 2017-09-27 |
| (45) | Date of publication and mention of the grant of the patent | 2020-02-26 |
| (46) | Date of publication of the claims translation | 2020-05-11 |
| (30) | Number | Date | Country code |
| 165419 P | 2009-03-31 | US | |
| 165447 P | 2009-03-31 | US |
| (72) |
Zhang, Jinkun, US
Dziewanowska, Zofia E, US
Belder, Rene, US
Henderson, Ian, US
Bogardus, Joseph B, US
Zhang, Zhaoying, US
|
| (73) |
Ligand Pharmaceuticals Inc.,
3911 Sorrento Valley Boulevard Suite 110, San Diego, CA 92121,
US
|
| (74) |
Stanislava TELEIŠIENĖ,
UAB "Brainera", Taikos 235-17, LT-05213 Vilnius,
LT
|
| (54) | Bifenilsulfonamido endotelino ir angiotenzino II receptoriaus antagonistas, skirtas glomerulosklerozės ir IgA indukuotos nefropatijos gydymui |
| A DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONISTS TO TREATGLOMERULOSCLEROSIS |
| Payment date | Validity (years) | Amount | |
| 2026-03-03 | 17 | 347.00 EUR |
| 2027-03-29 |